| 臺大學術典藏 |
2021-10-14T02:46:15Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; CHAO-YUAN HUANG; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-10-14T02:46:15Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.; Hsu C.-H.; CHAO-YUAN HUANG; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-10-14T02:46:14Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.; Hsu C.-H.; Hour T.-C.; Cheng A.-L.; CHAO-YUAN HUANG; Huang K.-H.; Chen J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-10-14T02:46:09Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; CHAO-YUAN HUANG; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-10-14T02:45:36Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.; Cheng J.C.-H.; CHAO-YUAN HUANG; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-17T07:13:03Z |
Corrigendum to “Morbidity and mortality of very low birth weight infants in Taiwan—Changes in 15 years: A population based study” [Journal of the Formosan Medical Association 115 (2016) 1039–1045](S0929664616303461)(10.1016/j.jfma.2016.10.011)
|
Su Y.-Y.; Wang S.-H.; Chou H.-C.; CHIEN-YI CHEN; Hsieh W.-S.; Tsao P.-N.; Tsou K.-I.; Hsu C.-H.; Mu S.-C.; Lin H.-C.; Huang C.-C.; Hsieh K.-S.; Taiwan Premature Infant Follow-up Network |
| 臺大學術典藏 |
2021-09-17T07:13:03Z |
Morbidity and mortality of very low birth weight infants in Taiwan—Changes in 15 years: A population based study
|
Su Y.-Y.; Wang S.-H.; Chou H.-C.; CHIEN-YI CHEN; Hsieh W.-S.; Tsao P.-N.; Tsou K.-I.; Hsu C.-H.; Mu S.-C.; Lin H.-C.; Huang C.-C.; Hsieh K.-S.; Taiwan Premature Infant Follow-up Network |
| 臺大學術典藏 |
2021-09-09T05:25:26Z |
Effect of polystyrene and silica compositions on formation of raspberry-like hollow nanoparticles: synthesis strategy and morphological study
|
Pham Q.-T.; ZONG-HAN YAO; Wu Y.-T.; Hsu C.-H.; Chern C.-S. |
| 臺大學術典藏 |
2021-09-04T03:10:22Z |
Orbital hemangiopericytoma in an Asian population
|
Hsu C.-H.; Wei Y.-H.; Peng Y.; SHU-LANG LIAO |
| 臺大學術典藏 |
2021-09-02T00:09:08Z |
A DAG-Based Algorithm for Obstacle-Aware Topology-Matching On-Track Bus Routing
|
Hsu C.-H;Hung S.-C;Chen H;Sun F.-K;Chang Y.-W.; Hsu C.-H; Hung S.-C; Chen H; Sun F.-K; Chang Y.-W.; YAO-WEN CHANG |
| 臺大學術典藏 |
2021-09-02T00:04:38Z |
Satellite-UAV-MEC Collaborative Architecture for Task Offloading in Vehicular Networks
|
Chao Y.-H;Chung C.-H;Hsu C.-H;Chiang Y;Wei H.-Y;Chou C.-T.; Chao Y.-H; Chung C.-H; Hsu C.-H; Chiang Y; Wei H.-Y; Chou C.-T.; CHUN-TING CHOU |
| 臺大學術典藏 |
2021-09-02T00:04:18Z |
High Speed Mach Zehnder Modulator with Low Series Resistance Phase Shifter Loaded in Traveling Wave Electrode
|
Ku K.-N;Chang P.-C;Wang C.-C;Lin C.-Y;Hsu C.-H;Chen T.-H;Huang C.-Y;Lee C.-S;Chen Y.-F;Chou K.-W;Chen S.-C;Lee M.-C;Lin C.-C;Chu M.-T;Wu C.-I.; Ku K.-N; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:04:15Z |
A Low Power CMOS Driver Integrated with Mach-Zehnder Modulator for PAM4 Optical Transmissions
|
Lee T.-H;Zhang J;Hong S;Hsu C.-H;Li S.-H;Chen S.-C;Shyh-Shyuan S;Wu C.-I;Hsu S.S.H.; Lee T.-H; Zhang J; Hong S; Hsu C.-H; Li S.-H; Chen S.-C; Shyh-Shyuan S; Wu C.-I; Hsu S.S.H.; CHIH-I WU |
| 臺大學術典藏 |
2021-09-02T00:04:15Z |
Analysis of Racetrack-Coupled Mach Zehnder Interferometer for High-Speed Communication
|
Ku K.-N;Chang P.-C;Wang C.-C;Lin C.-Y;Hsu C.-H;Chen T.-H;Huang C.-Y;Wun S.-J;Lee C.-S;Chen S.-C;Lee M.-C;Lin C.-C;Wu C.-I.; Ku K.-N; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:04:14Z |
A Frequency Digital Pre-Distortion Compensation Method for FMCW LiDAR System
|
Chen T.-H;Huang C.-Y;Shia T.K;Wun S.-J;Hsu C.-H;Ku K.-N;Lee C.-S;Lin C.-Y;Chang P.-C;Wang C.-C;Chen S.-C;Lin C.-C;Wu C.I.; Chen T.-H; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:04:14Z |
A frequency digital pre-distortion compensation method for FMCW LiDAR system
|
Chen T.-H;Huang C.-Y;Shia T.K;Wun S.-J;Hsu C.-H;Ku K.-N;Lee C.-S;Lin C.-Y;Chang P.-C;Wang C.-C;Chen S.-C;Lin C.-C;Wu C.-I.; Chen T.-H; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-01T02:02:42Z |
Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers
|
Hsu C.-H.; Yeh K.-H.; Chen L.-T.; Liu J.M.; Jan C.-M.; Lin J.-T.; Chen Y.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:40Z |
A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers
|
Yeh K.-H.; ANN-LII CHENG; Lin M.-T.; Hong R.-L.; Hsu C.-H.; Lin J.-F.; Chang K.-J.; Lee P.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:39Z |
Thymic carcinoma with autoimmune syndrome: Successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin
|
Hsu C.-H.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:33Z |
Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil
|
Yeh K.-H.; Yeh S.-H.; Hsu C.-H.; Wang T.-M.; Ma I.-F.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:33Z |
Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil
|
Hsu C.-H.; Yeh K.-H.; Lui L.T.; Lee Y.-C.; Bu C.-F.; Wang H.-P.; Lin J.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:33Z |
Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis
|
Chuang S.E.; Kuo M.L.; Hsu C.H.; Chen C.R.; Lin J.K.; Lai G.M.; Hsieh C.Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:32Z |
Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel
|
Hsu C.-H.; Chen M.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:30Z |
Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma
|
Hsu C.-H.; Chen J.; Wu C.-Y.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:30Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Lin C.-C.; Hsu C.-H.; Chen J.; Tsai T.-C.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:29Z |
Pre-clinical and early-phase clinical studies of curcumin as chemopreventive agent for endemic cancers in Taiwan.
|
Hsu C.H.; Chuang S.E.; Hergenhahn M.; Kuo M.L.; Lin J.K.; Hsieh C.Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:29Z |
Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma
|
Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:29Z |
Prognostic value of multidrug resistance 1, glutathione-S-transferase-π and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy
|
Hsu C.-H.; Chen C.-L.; Hong R.-L.; Chen K.-L.; Lin J.-F.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:28Z |
P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection
|
Liang J.-T.; Huang K.-C.; Cheng Y.-M.; Hsu H.-C.; ANN-LII CHENG; Hsu C.-H.; Yeh K.-H.; Wang S.-M.; Chang K.-J. |
| 臺大學術典藏 |
2021-09-01T02:02:27Z |
The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells
|
Hergenhahn M.; Soto U.; Weninger A.; Polack A.; Hsu C.-H.; ANN-LII CHENG; R?sl F. |
| 臺大學術典藏 |
2021-09-01T02:02:27Z |
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection
|
Liang J.-T.; Huang K.-C.; Lai H.-S.; Lee P.-H.; Cheng Y.-M.; Hsu H.-C.; ANN-LII CHENG; Hsu C.-H.; Yeh K.-H.; Wang S.-M.; Tang C.; Chang K.-J. |
| 臺大學術典藏 |
2021-09-01T02:02:26Z |
Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin
|
Hsu C.-H.; Hergenhahn M.; Chuang S.-E.; Yeh P.-Y.; Wu T.-C.; Gao M.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:26Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.; ANN-LII CHENG; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:25Z |
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma
|
ANN-LII CHENG; Hsiung C.A.; Su I.-J.; Chen P.-J.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J. |
| 臺大學術典藏 |
2021-09-01T02:02:22Z |
Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy
|
Hsu C.-H.; Hsu H.-C.; Chen H.-L.; Gao M.; Yeh P.-Y.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:21Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C.; Shen Y.-C.; Yang C.-H.; Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:21Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:18Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H.; Lu Y.S.; Hsu C.H.; Lin J.F.; Chao H.J.; Huang T.C.; Chung C.Y.; Chang C.S.; Yang C.H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:15Z |
Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro
|
Hsu C.-H.; Gao M.; Chen C.-L.; Yeh P.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:15Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Yang C.-H.; Chen M.-C.; ANN-LII CHENG; Hsu C.-H.; Yeh K.-H.; Yu Y.-C.; Whang-Peng J.; Yang P.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:15Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:14Z |
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients
|
Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; ANN-LII CHENG; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; Chen P.-J. |
| 臺大學術典藏 |
2021-09-01T02:02:13Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.; ANN-LII CHENG; Hsu C.; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2021-09-01T02:02:12Z |
A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus
|
Pei Y.Y.; Kuo S.-H.; Yeh K.-H.; Chuang S.-E.; Hsu C.-H.; Wen C.C.; Lin H.-I.; Gao M.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:11Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Chen J.; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:09Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Wang H.-P.; Lee J.-M.; Yeh K.-H.; Yang C.-H.; Lin J.-T.; ANN-LII CHENG; Lee Y.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:09Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:08Z |
Clinical studies with curcumin
|
Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:08Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.; ANN-LII CHENG; Hsu C.-H.; Lu Y.-S.; Hsu C.; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:07Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Lin C.-C.; Hsu C.; Hsu C.-H.; Hsu W.-L.; ANN-LII CHENG; Yang C.-H. |
